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Abstract
Background: An estimated up to 7% of high-risk cardiac surgery patients return to the operating room for
bleeding. Aprotinin was used extensively as an antifibrinolytic agent in cardiac surgery patients for over 15 years
and it showed efficacy in reducing bleeding. Aprotinin was removed from the market by the U.S. Food and Drug
Administration after a large prospective, randomized clinical trial documented an increased mortality risk associated
with the drug. Further debate arose when a meta-analysis of 211 randomized controlled trials showed no risk of
renal failure or death associated with aprotinin. However, only patients with normal kidney function have been
studied.
Methods: In this study, we look at a single center clinical trial using patients with varying degrees of baseline
kidney function to answer the question: Does aprotinin increase odds of death given varying levels of preoperative
kidney dysfunction?
Results: Based on our model, aprotinin use was associated with a 3.8-fold increase in odds of death one year later
compared to no aprotinin use with p-value = 0.0018, regardless of level of preoperative kidney dysfunction after
adjusting for other perioperative variables.
Conclusions: Lessons learned from our experience using aprotinin in the perioperative setting as an antifibrinolytic
during open cardiac surgery should guide us in testing future antifibrinolytic drugs for not only efficacy of
preventing bleeding, but for overall safety to the whole organism using long-term clinical outcome studies,
including those with varying degree of baseline kidney function.
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Background
Approximately one million cardiac surgeries are per-
formed in the United States every year. Of these, about
200,000 can be classified as complex procedures, such
as repeat coronary artery bypass grafting (CABG), valve
replacements, and combined CABG with valve repairs/
replacements. One of the reasons these procedures are
labeled as complex is because they carry a significant
increased risk of perioperative bleeding. An estimated
2.98% to 6.96% of high-risk cardiac operation patients
return to the operating room due to bleeding [1]. Apro-
tinin (Bayer Pharmaceutical Corporation, West Haven,
Connecticut), an antifibrinolytic agent, has been used
extensively since a study showed that it reduced the
need for blood transfusions during repeat cardiac sur-
gery [2]. Since then, other clinical trials have confirmed
aprotinin’s efficacy in reducing the need for blood trans-
fusions during these high-risk cardiac procedures [3,4].
The safety of aprotinin was brought into question in
2006 when a study revealed an increased risk of renal
failure, myocardial infarction, and stroke [5]. In 2008,
aprotinin was removed from the market after a large
prospective, randomized clinical trial documented an
increased mortality risk associated with the drug [6].
Further debate arose when a meta-analysis of 211 ran-
domized controlled trials showed no increased risk of
renal failure or death associated with aprotinin [4]. The
ongoing debate about aprotinin’s safety prompted us to
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asked two specific questions: 1) What association does
aprotinin have on all causes of mortality given varying
levels of preoperative kidney dysfunction, and 2) What
association does the drug have on all causes of mortality
rates one year later in the same group of patients?
Based on the previously mentioned studies, we proved
that aprotinin increases the odds of death regardless of
t h el e v e lo fap r e o p e r a t i v ek i d n e yd y s f u n c t i o ni nt h e s e
respective cohort patients.
Methods
This retrospective, single-center study compared aproti-
nin versus no aprotinin use during complex cardiac sur-
gery between October 2003 and October 2005. The
study was conducted at The Ohio State University Med-
ical Center in Columbus, Ohio. A total of 1,644 complex
cardiac procedures were done during this two-year per-
iod, which included repeat CABG, valve replacements,
and combined CABG with valve repairs/replacements.
Non-complex cases, such as primary coronary artery
bypass surgery, were specifically excluded in an attempt
to avoid the statistical bias that aprotinin tends to be
used in more complex surgeries, which inherently carry
a greater morbidity and mortality risk [7]. The patient
received the drug or no drug per the surgeons’ request.
After obtaining approval from our institutional review
board, we retrieved perioperative data from our institu-
tion’s thoracic surgery, perfusion, and general electronic
medical record databases. From the 1,644 cases, the
Center for Biostatistics randomly selected 251 with vary-
ing degrees of renal dysfunction for analysis.
Twenty data points per patient were collected, includ-
ing preoperative and postoperative kidney function,
patient demographics, medical comorbidities, intrao-
perative variables, aprotinin administration, postopera-
tive hemodialysis requirements, and one-year mortality
(Table 1). Glomerular filtration rate, a measure for kid-
ney function, was estimated using the Modification of
Diet in Renal Disease study equation formula. This took
into account serum creatinine measurement, age, sex,
and race. The estimated glomerular filtration rate
(eGFR) calculation was recorded in milliliters per min-
ute. The decision to treat with aprotinin was based on
surgeon preference. Follow-up data, including all causes
of mortality at one year, were obtained using records
from the electronic medical record database.
Statistical analysis
Categorical demographic and clinical characteristics of
patients were compared between the treatment and con-
trol groups using Chi-squared or Fisher exact tests as
appropriate (Table 1). Continuous characteristics were
compared between the treatment and control groups
using Student t tests or Wilcoxon rank sum test where
appropriate. The relationship between one-year mortal-
ity as the outcome variable and aprotinin treatment was
analyzed using a multivariate logistic regression model
that adjusted for other variables determined to be signif-
icantly related to mortality. Additional variables were
checked for potential confounding or effect modification
but did not make it into the final model as their effect
on the relationship between aprotinin treatment and the
outcome was minimal. We also adhered to the general
guideline to include no more than one variable per 10
patients in the group that experienced the outcome
event of interest. All statistical analyses were performed
using SAS 9.2 (SAS, Carey, N.C.).
Results
A total of 1,644 patients underwent complex cardiac
surgery between 2003 and 2005. From this population,
251 were randomly selected for analysis. From this
Table 1 Baseline Characteristics of Patients, According to
Treatment Group
No Aprotinin
Mean (SD)
Aprotinin
Mean (SD)
p-value
Age 61.1 (12.7) 64.5 (14.1) 0.045
Height (cm) 171.6 (8.9) 171.6 (10.6) 0.999
Weight (kg) 91.1 (22.9) 86.0 (20.5) 0.062
Lowest HCT on bypass 23.1 (4.8) 21.6 (4.7) 0.01
Blood glucose (on bypass) 231.6 (61.6) 245.8 (74.6) 0.10
Blood glucose
(48 hrs postoperative)
202.1 (59.9) 216.5 (80.01) 0.11
CPB duration 75.9 (56.9) 113.8 (64.3) < 0.001
RBC transfusion on bypass 1.27 (1.92) 2.13 (2.48)
Prime volume 575.0 (205.2) 588.6 (324.3) 0.71
UOP on pump 261.5 (241.9) 287.3 (290.9) 0.51
No Aprotinin
No. (%)
Aprotinin
No. (%)
p-value
Male 79 (68.1) 94 (70.15) 0.73
Mild renal failure 45 (38.79) 45 (33.33) 0.55
Moderate renal failure 39 (33.62) 45 (33.33)
Severe renal failure 32 (27.59) 45 (33.33)
Diabetes 49 (42.24) 51 (38.06) 0.50
COPD none 100 (86.21) 115 (85.19) 0.69
COPD mild 7 (6.0) 7 (5.2)
COPD mod 8 (6.9) 9 (6.7)
COPD severe 1 (0.9) 4 (3.0)
Hypertension 90 (77.6) 110 (81.5) 0.44
Diabetes 49 (42.2) 51 (38)
Peripheral vascular disease 17 (14.7) 28 (20.7) 0.21
Myocardial infarction 44 (37.9) 52 (38.5) 0.92
Congestive heart failure 42 (36.2) 83 (61.5) < 0.001
One year mortality 20 (17.2) 43 (32.1) 0.007
COPD - chronic obstructive pulmonary disease; CPB - cardiopulmonary bypass;
HCT - hematocrit; RBC - red blood cell; UOP - urine output
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of incomplete data sets. A total of 212 subjects were
included in our final statistical model.
Statistical analysis revealed three factors, other than
aprotinin, that were significantly associated with mortal-
ity (Table 2). These factors were controlled in a multi-
variate logistic regression model. Based on this model,
aprotinin use was associated with a 3.8-fold increase in
odds of death compared to no aprotinin use (p =
0.0018) regardless of the level of preoperative kidney
dysfunction after adjusting for other perioperative vari-
ables. The other three variables found to be significantly
associated with death were diabetes, packed red blood
cell transfusion on cardiopulmonary bypass, and 48-
hour postoperative eGFR. In our model, diabetes was
associated with a 2.2-fold increase in odds of death
compared with non-diabetic patients (p = 0.0312) (Table
3). For packed red blood cell transfusion, the odds of
death increased by 28% for every unit given while on
bypass (p = 0.0018). Lastly, for every one unit (ml/min)
increase in eGFR, the odds of death decreased by 2.4%.
As expected, patients had varying levels of kidney dys-
function preoperatively, though level of kidney dysfunc-
tion did not differ significantly between the two groups.
In our model, preoperative kidney function as a contin-
uous or categorical variable did not significantly interact
with aprotinin. This indicates that the increased odds of
death in aprotinin-treated patients were the same across
each level of kidney function.
The rates of postoperative hemodialysis were low for
both drug and no drug groups. Only one patient in the
no drug group and two patients in the aprotinin group
required postoperative hemodialysis.
Discussion
The primary new finding in our study is that aprotinin
use, irrespective of the level of preoperative renal dys-
function, was associated with a 3.8-fold increase in odds
ratio of death one year postoperatively. While previous
studies have documented an increase in mortality
associated with worsening preoperative kidney dysfunc-
tion [8,9], our model found no interaction between
aprotinin and preoperative kidney dysfunction. Thus,
our data supports the hypothesis that aprotinin use was
associated with a 3.8-fold increase in odds of death
compared to no aprotinin use (p = 0.0018) regardless of
the level of a preoperative kidney dysfunction after
adjusting for other perioperative variables.
This finding coincides with the Blood Conservation
Using Antifibrinolytics in a Randomized Trial [6] and
further supports the decision to remove aprotinin from
the market. Our results support the opinion that the
ability of aprotinin to reduce blood loss during complex
cardiac surgery does not outweigh the risk of death
associated with the drug. Furthermore, the continued
availability of the lysine analogues, such as aminocaproic
acid and tranexamic acid, lends little credibility to the
continued use of aprotinin. Though there is no clear
data showing the lysine analogues to be equally as effi-
cacious as aprotinin [7,10], the risks of aprotinin likely
do not outweigh the benefits.
There has been a certain degree of controversy over
aprotinin’s effect on kidney function postoperatively.
Several previous retrospective studies have shown apro-
tinin to be associated with an increased risk of post-
operative renal failure [11,12]. In contrast, the only
prospective, randomized, placebo-controlled trial to
investigate aprotinin’s effects on kidney function post-
operatively showed no significant difference between
drug and control groups [13]. Furthermore, several ret-
rospective studies have shown no increased incidence of
dialysis in aprotinin-treated patients compared with con-
trol [14,15]. Our study showed no increase in hemodia-
lysis in the aprotinin versus no aprotinin group.
However, given the low rates of hemodialysis in both of
our groups, it is possible that we missed a significant
rise in risk of renal failure. It should also be noted that
we were unable to obtain definitive causes of death dur-
ing our data collection.
Table 2 Multivariate Logistic Regression for One Year
Postoperative Mortality in 184 Patients Showing
Aprotinin Increased Death*
Effect Odds Ratio (95% CI) p-value
Aprotinin vs. control 3.830 (1.649, 8.893) 0.0018
Diabetes 2.236 (1.075, 4.651) 0.0312
PRBC transfusion on bypass 1.282 (1.096, 1.498) 0.0018
eGFR 48 hours postoperatively 0.976 (0.958, 0.994) 0.0079
CI - confidence interval; eGFR - estimated glomerular filtration rate; PRBC -
packed red blood cells
* Excluded were 39 patients with missing values for at least one of the
covariates in the model. The Hosmer-Lemeshow goodness of fit chi-square
test statistic was 3.62 (P = 0.89).
Table 3 Results of Multivariate Logistic Regression for
One Year Postoperative Mortality in 184 Patients*
Effect Point Estimate 95% CI p-value
Aprotinin vs. control 6.474 2.270 18.469 0.0005
Diabetes vs. no Diab 2.304 0.941 5.645 0.0679
urine_output 0.996 0.994 0.999 0.0019
Prime_Vol 1.002 1.000 1.003 0.0391
Blood_Gluc_High_48_h 1.007 1.000 1.013 0.0498
RBC_trans 1.422 1.176 1.720 0.0003
Initial_Creatinine_m 0.595 0.364 0.974 0.0388
CI - confidence interval; Gluc - glucose; RBC - red blood cell; Vol - volume
*Excluded were 67 patients with missing values for at least one of the
covariates in the model. The Hosmer-Lemeshow goodness of fit chi-square
test statistic was 3.62 (P = 0.89).
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be significantly associated with mortality. We discuss
these, as it was necessary to include them in our final
statistical model. We found that the presence of dia-
betes, increased blood transfusions on bypass, and
decreased eGFR all were associated with increased mor-
tality. These findings are not surprising, and similar
mortality associations have been demonstrated in the lit-
erature for diabetes [16-19] and red blood cell transfu-
sion [20-25].
Our findings, while significant and new, have some
limitations. The most significant of these limitations is
the retrospective nature of the study. Also, the small
number of deaths and our inability to document a cause
of death may have potentially masked an increased risk
of renal dysfunction as well as any other major organ
system failures. In addition, our preoperative baseline of
acute kidney dysfunction is non-standardized since there
is no agreed upon definition of grades of acute renal
dysfunction [26]. The aprotinin was administered to the
patient per surgeon preference.
Conclusions
The exact mechanism of increased mortality associated
with aprotinin is unknown; however, it has been specu-
l a t e dt h a ti tm a yb er e l a t e dt oi t ss y s t e m i ce f f e c to n
inflammation, oxidative stress, and bioactive molecules
in addition to the complex interaction between the
homeostatic, complement, and cytokine pathways in the
setting of ischemia and reperfusion [27,28]. Ray and
Stein [29] theorize that aprotinin’s potential increase in
mortality may simply be due to an over effectiveness of
antifibrinolysis when compared to the lysine analogues.
Perhaps the balance between procoagulatory and antic-
oagulatory effects is tipped too far in one direction by
aprotinin. Novel pathways may exist that could be exert-
ing deleterious affects on major organ systems. Regard-
less of speculation, it is clear that further research is
necessary to elucidate the exact mechanisms that cur-
rent and future antifibrinolytics exert on the whole
organism, including long-term effects. A more complete
understanding of their pathways will help to design
drugs in the future that are as effective as they are safe.
We believe that the lessons learned from our experience
of using aprotinin as an antifibrinolytic during open
h e a r ts u r g e r yi nt h ep a s ts h o u l dg u i d eu si nt e s t i n g
future drugs, which will not only focus on their efficacy
of preventing bleeding, but on overall safety to the
whole organism using long-term clinical outcome
studies.
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